Cargando…
Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients
Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861454/ https://www.ncbi.nlm.nih.gov/pubmed/36680159 http://dx.doi.org/10.3390/v15010119 |
_version_ | 1784874845550411776 |
---|---|
author | Thümmler, Laura Lindemann, Monika Horn, Peter A. Lenz, Veronika Konik, Margarethe Gäckler, Anja Boss, Kristina Theodoropoulos, Fotis Besa, Vasiliki Taube, Christian Brenner, Thorsten Witzke, Oliver Krawczyk, Adalbert Rohn, Hana |
author_facet | Thümmler, Laura Lindemann, Monika Horn, Peter A. Lenz, Veronika Konik, Margarethe Gäckler, Anja Boss, Kristina Theodoropoulos, Fotis Besa, Vasiliki Taube, Christian Brenner, Thorsten Witzke, Oliver Krawczyk, Adalbert Rohn, Hana |
author_sort | Thümmler, Laura |
collection | PubMed |
description | Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients from a severe or lethal course of infection. However, monoclonal antibodies are not always available or less effective against emerging SARS-CoV-2 variants. Convalescent plasma is more commonly available and may represent a good treatment alternative in low-income countries. We retrospectively evaluated outcomes in individuals treated with mAbs or convalescent plasma and compared the 30-day overall survival with a patient cohort that received supportive care due to a lack of SARS-CoV-2 specific therapies between March 2020 and April 2021. Our data demonstrate that mAb treatment is highly effective in preventing severe courses of SARS-CoV-2 infection. All patients treated with mAb survived. Treatment with convalescent plasma improved overall survival to 82% compared with 61% in patients without SARS-CoV-2 targeted therapy. Our data indicate that early convalescent plasma treatment may be an option to improve the overall survival of high-risk COVID-19 patients. This is especially true when other antiviral drugs are not available or their efficacy is significantly reduced, which may be the case with emerging SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-9861454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98614542023-01-22 Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients Thümmler, Laura Lindemann, Monika Horn, Peter A. Lenz, Veronika Konik, Margarethe Gäckler, Anja Boss, Kristina Theodoropoulos, Fotis Besa, Vasiliki Taube, Christian Brenner, Thorsten Witzke, Oliver Krawczyk, Adalbert Rohn, Hana Viruses Communication Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients from a severe or lethal course of infection. However, monoclonal antibodies are not always available or less effective against emerging SARS-CoV-2 variants. Convalescent plasma is more commonly available and may represent a good treatment alternative in low-income countries. We retrospectively evaluated outcomes in individuals treated with mAbs or convalescent plasma and compared the 30-day overall survival with a patient cohort that received supportive care due to a lack of SARS-CoV-2 specific therapies between March 2020 and April 2021. Our data demonstrate that mAb treatment is highly effective in preventing severe courses of SARS-CoV-2 infection. All patients treated with mAb survived. Treatment with convalescent plasma improved overall survival to 82% compared with 61% in patients without SARS-CoV-2 targeted therapy. Our data indicate that early convalescent plasma treatment may be an option to improve the overall survival of high-risk COVID-19 patients. This is especially true when other antiviral drugs are not available or their efficacy is significantly reduced, which may be the case with emerging SARS-CoV-2 variants. MDPI 2022-12-30 /pmc/articles/PMC9861454/ /pubmed/36680159 http://dx.doi.org/10.3390/v15010119 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Thümmler, Laura Lindemann, Monika Horn, Peter A. Lenz, Veronika Konik, Margarethe Gäckler, Anja Boss, Kristina Theodoropoulos, Fotis Besa, Vasiliki Taube, Christian Brenner, Thorsten Witzke, Oliver Krawczyk, Adalbert Rohn, Hana Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients |
title | Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients |
title_full | Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients |
title_fullStr | Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients |
title_full_unstemmed | Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients |
title_short | Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients |
title_sort | early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated covid-19 high-risk patients |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861454/ https://www.ncbi.nlm.nih.gov/pubmed/36680159 http://dx.doi.org/10.3390/v15010119 |
work_keys_str_mv | AT thummlerlaura earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT lindemannmonika earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT hornpetera earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT lenzveronika earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT konikmargarethe earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT gackleranja earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT bosskristina earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT theodoropoulosfotis earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT besavasiliki earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT taubechristian earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT brennerthorsten earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT witzkeoliver earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT krawczykadalbert earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients AT rohnhana earlytreatmentwithmonoclonalantibodiesorconvalescentplasmareducesmortalityinnonvaccinatedcovid19highriskpatients |